Welcome to our dedicated page for iSpecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on iSpecimen stock.
iSpecimen Inc., headquartered in Lexington, MA, is a leading marketplace for human biospecimens. The company provides researchers with the specimens they need from the patients they want through its innovative iSpecimen Marketplace. This online platform connects healthcare organizations with access to patients and specimens with scientists in need of these vital resources.
Utilizing proprietary, cloud-based technology, iSpecimen enables researchers to intuitively search for specimens across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. This system allows for easy and compliant access to specimens, facilitating scientific discovery and advancing healthcare for all.
iSpecimen stands out by offering a unique value proposition to both researchers and partner sites. Researchers gain the necessary resources to drive their studies, while partner sites can contribute to biomedical discovery and benefit financially. The company caters to a global market, with operations spanning the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority of its revenue coming from the Americas.
In recent news, iSpecimen has achieved a sequential quarterly revenue growth of 75%, driven by enhanced operational efficiencies and new business initiatives. The company continues to expand its network by adding new suppliers and reinforcing existing relationships to provide researchers with increased access to highly sought-after biospecimens, especially for oncology research. Additionally, iSpecimen is making strides in quality control and assurance through digital AI histopathology services, enhancing data quality and operational efficiency.
For investors and media inquiries, iSpecimen's contacts at KCSA Strategic Communications are available for further information.
iSpecimen (Nasdaq: ISPC), a leading online marketplace for biospecimens, announced that CEO Christopher Ianelli will participate virtually in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. His presentation will be accessible on-demand starting May 24, 2022, at 7:00 a.m. ET. The conference aims to connect scientists with healthcare providers for medical research. iSpecimen’s platform facilitates searching for human biospecimens through a cloud-based network, enhancing medical discoveries.
iSpecimen Inc. (Nasdaq: ISPC) reported Q1 2022 revenue of approximately $2.5 million, down from $3.0 million year-over-year, impacted by the Ukraine-Russia conflict affecting supply chains. The company managed to transition $1.0 million in open purchase orders to other suppliers, demonstrating marketplace adaptability. Unique customers rose by 25% to 437, and supplier organizations increased to 205. General and administrative expenses rose to $1.8 million due to increased costs. Net loss for the quarter was about $2.4 million, with cash reserves at approximately $26.1 million.
iSpecimen Inc. (Nasdaq: ISPC) announced plans to report its financial results for Q1 2022 on May 10, 2022, before market opening. The company connects researchers with biospecimens through an online marketplace. A conference call will be held at 8:30 a.m. ET that same day, featuring CEO Christopher Ianelli and other executives. Interested participants can join via phone or webcast, with a replay available until May 24, 2022. iSpecimen specializes in facilitating medical research by linking scientists with healthcare providers for essential specimens.
iSpecimen (Nasdaq: ISPC) has launched an enhanced iSpecimen Marketplace® platform that improves search capabilities and data integration for biospecimen procurement. The updated interface features a Google-like search bar and advanced matching algorithms, allowing researchers to find the specific human biospecimens they need. Suppliers can access their inventories more easily, while new data fields enhance the search process. The marketplace remains free for both suppliers and researchers, aiming to streamline the connection between scientists and medical samples critical for research.
iSpecimen Inc. (Nasdaq: ISPC) has partnered with Acutis Diagnostics to enhance its biospecimen marketplace platform, introducing custom sequencing services for cancer and COVID-19 samples. This collaboration aims to streamline the research process by providing a single source for samples and corresponding sequencing data, improving researchers' ability to study genetic mutations linked to these diseases. Given the high demand for biospecimens related to cancer and COVID-19, this initiative is set to foster advancements in medical diagnostics and therapeutics.
iSpecimen (Nasdaq: ISPC) has announced that CEO Christopher Ianelli will participate in the Maxim Group’s 2022 Virtual Growth Conference from March 28-30, 2022. The corporate presentation will be available on-demand starting March 28, 2022, at 9:00 a.m. ET for all registrants. iSpecimen connects scientists with healthcare providers through its online marketplace for biospecimens essential for medical research. For more details about the conference or one-on-one meetings, attendees can reach out to Maxim representatives or KCSA Strategic Communications.
iSpecimen Inc. (Nasdaq: ISPC) announced its marketplace network has exceeded 200 healthcare providers, significantly enhancing access to biospecimens for medical research. This platform connects researchers with healthcare organizations, improving procurement efficiency for crucial samples such as tissues and biofluids. The diverse supplier network ensures a reliable flow of specimens, addressing potential shortages from global disruptions. The company emphasizes compliance and rigorous vetting for its suppliers to maintain high ethical and operational standards.
iSpecimen Inc. (Nasdaq: ISPC) reported a record FY 2021 revenue of $11.1 million, a 36% increase from FY 2020's $8.2 million. The revenue consisted of $8.0 million (72%) from non-COVID-19 related sources and $3.1 million (28%) from COVID-19. The company expanded its supplier network to 200 organizations and customer purchases grew to 415. iSpecimen raised $21 million in a private placement, enhancing its capabilities for biospecimen research. However, net loss increased to $9.0 million from $4.7 million in 2020.
iSpecimen (NASDAQ: ISPC) announced CEO Dr. Christopher Ianelli's participation in the Aegis Capital Corp. Virtual Conference from February 23-25, 2022. Dr. Ianelli will present on February 24 at 12:30 p.m. ET. Interested attendees can add the event to their calendars via an iCalendar link. iSpecimen operates an online marketplace for human biospecimens, enabling life scientists to connect with healthcare providers for research needs. For further inquiries or one-on-one meetings, contact KCSA Strategic Communications.
iSpecimen Inc. (NASDAQ: ISPC) will release its fourth quarter and full year financial results for 2021 on February 17, 2022, before market opening. An audio webcast will follow at 8:30 a.m. ET, featuring key executives including CEO Christopher Ianelli. Investors can join the live call at +1-877-425-9470 (U.S.) or +1-201-389-0878 (International). A replay option will be available until March 3, 2022. iSpecimen offers a marketplace for human biospecimens, connecting researchers with healthcare providers.
FAQ
What is the current stock price of iSpecimen (ISPC)?
What is the market cap of iSpecimen (ISPC)?
What is iSpecimen Inc.?
Where is iSpecimen Inc. headquartered?
How does the iSpecimen Marketplace work?
What kind of specimens does iSpecimen provide?
What recent achievements has iSpecimen made?
Who can benefit from using iSpecimen's services?
What regions does iSpecimen operate in?
How can researchers access iSpecimen's services?
How does iSpecimen ensure quality control?
How can investors get in touch with iSpecimen?
